Poor
Not Aligned
Patient Risk:
Moderate
Summary
Low alignment: many claims are unsupported by the provided label text (e.g., approval dates, pricing, patent/generic status, comparative risk and timing-to-effect). The evaluation also flags comparative statements as contradicted without label support, which is not a label-grounded determination.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin that works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (inhibits HMG-CoA reductase/cholesterol synthesis in the liver)
Lipitor is used to prevent cardiovascular events/heart disease outcomes (e.g., reduce the risk of myocardial infarction, stroke, revascularization procedures and angina).
1.1 Prevention of Cardiovascular Disease (listed risk reductions)
Lipitor is available in dosages including 10 mg, 20 mg, 40 mg, and 80 mg (atorvastatin calcium tablets).
3 Dosage Forms and Strengths (10, 20, 40, 80 mg)
Common adverse reactions associated with LIPITOR include muscle pain (myalgia), diarrhea, and nausea.
6.1 Clinical Trial Adverse Experiences (myalgia, diarrhea, nausea listed among common adverse reactions)
Unsupported Statements
Lipitor was first approved by the FDA in 1997.
No approval date information in the provided label sections.
Atorvastatin is the generic version of Lipitor.
No generic/brand equivalence statements in the provided label sections.
Atorvastatin contains the same active ingredient as Lipitor.
The label states atorvastatin calcium in tablets, but the provided sections do not explicitly confirm generic equivalence between Lipitor and atorvastatin.
Atorvastatin was first approved by the FDA in 2006.
No approval date information in the provided label sections.
Lipitor 20 mg average cost is around $140 for a 30-day supply and prices range from $100 to over $200.
No pricing information in the provided label sections.
Atorvastatin 20 mg average cost is around $30 for a 30-day supply and prices range from $20 to over $50.
No pricing information in the provided label sections.
Atorvastatin is cheaper than Lipitor because it is generic and not protected by a patent.
No patent protection or pricing rationale in the provided label sections.
Lipitor is a brand-name medication protected by a patent; Lipitor's patent expired in 2011; atorvastatin available as generic since 2006; market is highly competitive due to multiple generic manufacturers.
No patent/generic availability/market competitiveness information in the provided label sections.
Both Lipitor and atorvastatin can cause side effects including muscle pain, diarrhea, and nausea.
The label supports these adverse reactions for LIPITOR/atorvastatin class context, but the specific 'Both Lipitor and atorvastatin' equivalence is not explicitly supported in the provided sections. (Claim relies on brand-vs-generic framing not addressed in label text provided.)
Lipitor has been associated with a higher risk of liver damage compared to atorvastatin.
No brand-vs-generic comparative liver-damage risk statement is supported by the provided label text.
Lipitor has been associated with a higher risk of muscle damage compared to atorvastatin.
No brand-vs-generic comparative muscle-damage risk statement is supported by the provided label text.
Lipitor has been associated with a higher risk of interactions compared to atorvastatin.
No brand-vs-generic comparative interaction-risk statement is supported by the provided label text.
Atorvastatin has a lower risk of side effects compared to Lipitor.
No brand-vs-generic comparative side-effect risk statement is supported by the provided label text.
Atorvastatin has a lower risk of interactions compared to Lipitor.
No brand-vs-generic comparative interaction-risk statement is supported by the provided label text.
Atorvastatin can start working within a few weeks of taking the medication.
No time-to-effect statement is present in the provided label sections.
Both Lipitor and atorvastatin can interact with other medications including blood thinners and certain antibiotics.
The label provided includes warfarin and certain antibiotics/strong CYP3A4 inhibitors in specific contexts, but does not support a broad 'blood thinners' generalization beyond the specific warfarin statement included, nor does it support the brand-vs-generic framing.
Contradictions
Low
AI Statement
Lipitor has been associated with a higher risk of liver damage compared to atorvastatin.
Label Reference
Provided label sections do not contain a Lipitor-vs-atorvastatin comparative risk statement; 5.2 and 6.1 describe LIPITOR-related liver enzyme abnormalities without comparative brand-vs-generic conclusions.
Low
AI Statement
Lipitor has been associated with a higher risk of muscle damage compared to atorvastatin.
Label Reference
Provided label sections describe LIPITOR/atorvastatin myopathy/rhabdomyolysis risk (5.1, 6.1) but do not provide Lipitor-vs-atorvastatin comparative risk.
Important Omissions
No evaluation of key high-priority label content for contraindications and boxed warnings (the provided label sections include no boxed warning/contraindication text).
Importance:
High
No assessment of detailed monitoring recommendations and stopping/withholding instructions for skeletal muscle or liver dysfunction beyond general statements (e.g., specific monitoring and discontinuation language).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported or improperly framed (comparative brand-vs-generic risk, time-to-effect, and broad interaction/generalization). While these specific claims are not directly dosage guidance, incorrect safety-related comparisons and unverified statements can mislead risk interpretation. Additionally, contraindications/boxed warnings were not assessed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Many non-label claims (approval dates, pricing, patent/generic status, timing-to-effect) and unsupported comparative safety/interaction risk statements; also missing evaluation of contraindications/boxed warnings.
Suggested Improvement
Limit assertions to label-supported content in the provided sections. Remove or mark as unsupported claims about FDA approval years, pricing, patent/generic availability, brand-vs-atorvastatin comparative risk, and time-to-effect. Ensure evaluation includes contraindications/boxed warnings and specific monitoring/discontinuation recommendations present in the label.